We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
A federal jury ruled that Gilead Sciences must dole out $200 million in damages to Merck and Ionis Pharmaceuticals for patent infringement over the active ingredient sofosbuvir in Gilead’s blockbuster hepatitis C drugs. Read More
A three-judge panel for the U.S. Court of Appeals for the Federal Circuit has upheld two Depomed patents, enabling it to resume its lawsuit against Purdue Pharma. Read More
Merck won a key court victory late Tuesday with a jury concluding that two of Gilead Science’s blockbuster drugs infringe patents held by Merck & Co. and Ionis Pharmaceuticals. Read More